- Q1 2024 Cellectar Biosciences Inc Earnings Call TranscriptMay 14, 2024$3.18 (+3.92%)Earnings
- Q4 2023 Cellectar Biosciences Inc Earnings Call TranscriptMar 27, 2024$3.64 (-5.58%)Earnings
- Cellectar Biosciences Inc KOL Call TranscriptJan 19, 2024
- Cellectar Biosciences Inc at EBD Group Biotech Showcase TranscriptJan 09, 2024
- Cellectar Biosciences Inc Top-line Data Call TranscriptJan 08, 2024
- Q3 2023 Cellectar Biosciences Inc Earnings Call TranscriptNov 02, 2023$2.4 (+0.84%)Earnings
- Cellectar Biosciences Inc Annual Shareholders Meeting TranscriptJun 23, 2023
- Cellectar Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Cellectar Biosciences Inc at ROTH Conference TranscriptMar 13, 2023
- Cellectar Biosciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Cellectar Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference TranscriptJul 14, 2021
- Cellectar Biosciences Inc at Next Generation Targeted Cancer Therapies - The Cellectar Story! TranscriptOct 16, 2020
Q4 2023 Cellectar Biosciences Inc Earnings Call Transcript
Good morning and welcome to Cellectar Biosciences 2023 year-end earnings call. Today's call is being recorded.
Before we begin, I would like to remind everyone that statements made during this call relating to Cellectarâs expected future performance, future business prospects, or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could differ materially from those forecast due to the impact of many factors beyond the control of Cellectar. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events, or otherwise.
Participants are directed to the cautionary notes set forth in today's press release, which is available on the Investor Relations portion of the company's website as well as risk factors set forth in Cellectarâs annual
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)